CDC Panel Unanimously Recommends RSV Vaccines for Seniors

GSK and Pfizer win FDA approval and recommendations from CDC advisory committee for RSV vaccines in adults over 60.
The vaccines demonstrate strong protection over multiple RSV seasons with most needing only one dose.
Pricing and potential booster schedules are still being studied, but the vaccines could be available this fall.
RSV is a serious respiratory illness that hospitalizes tens of thousands of seniors and kills up to 10,000 older adults in the U.S. each year.
The recommendation paves the way for the first approved RSV vaccines to prevent a virus that until now had no authorized prevention options.